Corpus ID: 201682055

In vivo and in vitro evaluation of Lu-labeled DOTA-2-deoxy-D-glucose in mice . A novel radiopharmaceutical agent for cells imaging and therapy

@inproceedings{Liu2019InVA,
  title={In vivo and in vitro evaluation of Lu-labeled DOTA-2-deoxy-D-glucose in mice . A novel radiopharmaceutical agent for cells imaging and therapy},
  author={Huipan Liu and Liang Cai and Ling Zhou and Hongyuan Wei and Ying Zhong Xie},
  year={2019}
}
177 Objectives: Incorporation of lutetium-177 ( Lu) into suitable molecules that are implicated in cancer pathology represents a promising approach for the diagnosis and treatment of cancer. The goal of the present 177 study was to develop a novel Lu labeled radiopharmaceutical agent for both radioimaging and targeted radionuclide therapy. Animals and Methods: Given the synthetic versatility of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) ligand as a metal chelator and high… Expand

Figures from this paper

References

SHOWING 1-10 OF 36 REFERENCES
Synthesis and evaluation of 111In-labeled d-glucose as a potential SPECT imaging agent
The purpose of this study was to develop an efficient synthetic method for labeling d-Glucosamine with indium-111 (111In), and to investigate the imaging properties of the resulting radiotracer inExpand
Synthesis and evaluation of a technetium-99m-labeled diethylenetriaminepentaacetate-deoxyglucose complex ([99mTc]-DTPA-DG) as a potential imaging modality for tumors.
TLDR
The [(99m)Tc]-DTPA-DG complex is a potential imaging agent due to the ideal physical characteristics of the radionuclide, ease of preparation, low cost, early accumulation and the preference for the renal route of excretion. Expand
18F-FDG and Other Labeled Glucose Derivatives for Use in Radionuclide Diagnosis of Oncological Diseases (Review)
This review addresses progress in the radionuclide diagnosis of oncological diseases using radiopharmaceutical preparations (RPP) based on labeled glucose derivatives. Most attention is paid toExpand
68Ga tagged dendrimers for molecular tumor imaging in animals.
TLDR
The animal PET imaging data showed that maximum tumor to background ratio was obtained at 1h post injection of 68Ga DOTA-G4 PAMAM dendrimer suggesting that the designed nanoprobes could efficiently target tumor tissues and be retained there due to their enhanced permeability and retention (EPR) effect. Expand
Peptide-targeted radionuclide therapy for melanoma.
TLDR
Peptide-targeted radionuclide therapy for melanoma will likely contribute in an adjuvant setting, once the primary tumor has been surgically removed, to treat metastatic deposits and for treatment of end-stage disease. Expand
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
TLDR
This phase I study demonstrates for the first time that pretargeting with bsMAb TF2 and radiolabelled IMP288 in patients with CEA-expressing CRC is feasible and safe. Expand
Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment.
TLDR
The sensitivity compared to conventional anatomical imaging modalities and especially the possibility that (111)In-P may change therapeutic management into up one fourth of the patients is described. Expand
Initial and subsequent approach for the synthesis of 18FDG.
TLDR
Advances have largely overcome the limitations of the 110-minute half-life of 18F so that 18FDG is now available to most regions of the United States from a number of central production sites, and avoids the need for an on-site cyclotron and chemistry laboratory and has opened up the use of 18 FDG to institutions that have a positron emission tomography scanner (or other imaging device) but no cyclotrons or chemistry infrastructure. Expand
Cellular toxicity and apoptosis studies in osteocarcinoma cells, a comparison of 177Lu-EDTMP and Lu-EDTMP.
TLDR
These studies indicate that the 177Lu-EDTMP binds to mineralized bone cells and induces apoptotic cell death in MG63 cells, the most promising bone pain palliative agent. Expand
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
TLDR
This review discusses the practical issues of administering Lu PSMA, and gives an overview of the findings from currently published trials in regards to treatment response rates, expected toxicities and safety. Expand
...
1
2
3
4
...